MYH7
ENSG00000092054
Target class
Unclassified protein
Chromosome
14
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- CMD1S
- Target name
- MYH7
- Gene name
- Myosin heavy chain 7
- Gene symbol
- MYH7
- Protein name
- Myosin-7 (Myosin heavy chain 7) (Myosin heavy chain slow isoform) (MyHC-slow) (Myosin heavy chain, cardiac muscle beta isoform) (MyHC-beta)
- CMH1
- MPD1
- Gene biotype
- Protein coding
- Gene family
- Myosin heavy chains, class II|MicroRNA protein coding host genes
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 36
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 4,513.66
- Tissue specificity (Gini)
- 0.956
- Tissue specificity (tau)
- 0.982
- KEGG gene identifiers
- hsa:4625
- Protein interaction confidence
- 0.864323
- Protein interaction partners
- 62
- End position
- 23436137
- Start position
- 23412733
- Chromosome
- 14
- Strand
- Reverse
- Cytoplasm, myofibril . Cytoplasm, myofibril, sarcomere . Note=Thick filaments of the myofibrils. .
- Tissue specificity (tau)
- 0.981788
- Expression inequality (Gini)
- 0.955655
Expression in transcripts per million
- Heart - Left Ventricle
- 4,513.66
- Muscle - Skeletal
- 3,692.76
- Heart - Atrial Appendage
- 592.18
- Pancreas
- 5.3
- Brain - Hypothalamus
- 4.9
Expression in transcripts per million
- Heart - Left Ventricle4,513.66
- Muscle - Skeletal3,692.76
- Heart - Atrial Appendage592.18
- Pancreas5.3
- Brain - Hypothalamus4.9
- Brain - Nucleus accumbens (basal ganglia)3.13
- Brain - Caudate (basal ganglia)3.12
- Pituitary3.03
- Testis2.69
- Minor Salivary Gland2.5
- Brain - Cortex2.45
- Brain - Putamen (basal ganglia)2.42
- Brain - Frontal Cortex (BA9)2.23
- Brain - Anterior cingulate cortex (BA24)1.91
- Artery - Coronary1.69
- Nerve - Tibial1.68
- Artery - Tibial1.66
- Lung1.54
- Brain - Hippocampus1.45
- Brain - Amygdala1.41
- Skin - Sun Exposed (Lower leg)1.39
- Skin - Not Sun Exposed (Suprapubic)1.35
- Artery - Aorta1.3
- Adipose - Subcutaneous1.29
- Colon - Sigmoid1.25
And 29 more, listed on the interactive page.
- GO:0002026
- GO:0002027
- GO:0003009
- GO:0006936
- GO:0006941
- GO:0007512
- GO:0014728
- GO:0030049
- GO:0031449
- GO:0046034
- GO:0055010
- GO:0060048
- GO:0005859
- GO:0016459
- GO:0030017
- GO:0032982
- GO:0000146
- GO:0005515
Related records
Trials (65)
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
- A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
- A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
- A Study of CK-1827452 Infusion in Stable Heart Failure
- A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
- A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
- A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
- A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
- A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
- A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
- A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Drugs (3)
- Danicamtiv Cardiac myosin activator
- Mavacamten Cardiac myosin inhibitor
- Omecamtiv mecarbil Cardiac myosin activator